Pfizer’s $10 billion licensing deal with Innovent, alongside rising U.S. debate over expanding COINS Act restrictions on China biotech investment, signals a structural shift in global pharma strategy. The announcement, combined with Astellas’ Xtandi patent cliff response and ASCO scrutiny
